Lee B R, Jabbour M E, Marshall F F, Smith A D, Jarrett T W
James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA.
J Endourol. 1999 May;13(4):289-94. doi: 10.1089/end.1999.13.289.
Transitional cell carcinoma (TCC) of the renal collecting system traditionally has been managed by open nephroureterectomy with en bloc resection of a bladder cuff. However, for a select patient population with a solitary kidney or bilateral disease, the morbidity and mortality associated with chronic renal insufficiency and dialysis is deterring. In these situations, a more conservative approach such as antegrade percutaneous resection should be considered. The long-term disease-free outcome of percutaneous management in comparison with open nephroureterectomy has not been previously reported. We evaluated our experience with two surgical approaches to treat upper tract TCC: percutaneous resection and nephroureterectomy/nephrectomy to assess the clinical efficacy of these surgical modalities.
We retrospectively identified 162 patients who had clinically localized TCC of the upper urinary tract. Records were reviewed to identify those with 13-year follow-up (N = 110) in respect to tumor grade, stage, disease-free status, length of cancer-specific survival, and overall survival. Statistical analysis of the results of open nephroureterectomy/nephrectomy (N = 60) and percutaneous resection (N = 50) was performed using Kaplan-Meier survival curves and Student's t-test.
All patients had disease in clinical stage Ta through T3. During a mean follow-up of 46.6 (range 6-150) months, grade 1 disease demonstrated little invasive potential. Of the disease-specific deaths, 60% (17/26) were of patients with grade 3 lesions, with a mean cancer survival period of 15.2 months after the initial procedure. Disease-specific survival rates after open and percutaneous approaches for grade 2 disease were 53.8 and 53.3 months, respectively (P > 0.05).
Tumor grade appeared to be the most important prognostic indicator in patients with renal TCC regardless of the surgical approach. Grade 3 tumors were more aggressive, presenting in an advanced stage with invasion, and recurrences were usually associated with metastasis. In this population, nephroureterectomy is warranted if the patient is a surgical candidate. The percutaneous option for grade 1 or 2 disease may be extended beyond the population with solitary kidneys and a risk of chronic renal failure to be offered to healthy individuals with normal contralateral kidneys who are willing to abide by a strict and lengthy follow-up.
传统上,肾集合系统移行细胞癌(TCC)的治疗方法是开放性肾输尿管切除术并整块切除膀胱袖口。然而,对于患有孤立肾或双侧疾病的特定患者群体,与慢性肾功能不全和透析相关的发病率和死亡率令人望而却步。在这些情况下,应考虑采用更保守的方法,如顺行性经皮切除术。与开放性肾输尿管切除术相比,经皮治疗的长期无病结局此前尚未见报道。我们评估了我们采用两种手术方法治疗上尿路TCC的经验:经皮切除术和肾输尿管切除术/肾切除术,以评估这些手术方式的临床疗效。
我们回顾性确定了162例临床上局限于上尿路的TCC患者。查阅记录以确定那些有13年随访资料的患者(N = 110),内容包括肿瘤分级、分期、无病状态、癌症特异性生存时长和总生存情况。使用Kaplan-Meier生存曲线和学生t检验对开放性肾输尿管切除术/肾切除术(N = 60)和经皮切除术(N = 50)的结果进行统计分析。
所有患者的临床分期为Ta至T3期。在平均46.6个月(范围6 - 150个月)的随访期间,1级疾病几乎没有侵袭潜能。在疾病特异性死亡病例中,60%(17/26)为3级病变患者,初次手术后的平均癌症生存期为15.2个月。2级疾病经开放手术和经皮手术治疗后的疾病特异性生存率分别为53.8个月和53.3个月(P > 0.05)。
无论采用何种手术方法,肿瘤分级似乎都是肾TCC患者最重要的预后指标。3级肿瘤侵袭性更强,多在晚期出现侵袭,复发通常与转移相关。在这一患者群体中,如果患者是手术候选人,则有必要进行肾输尿管切除术。对于1级或2级疾病,经皮手术选择可能不仅适用于孤立肾且有慢性肾衰竭风险的患者群体,也可提供给对侧肾脏正常且愿意接受严格且长期随访的健康个体。